Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jupiter Neurosciences, Inc. - SIC # 2840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
JUNS
Nasdaq
2840
jupiterneurosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jupiter Neurosciences, Inc.
Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
- Jun 9th, 2026 5:00 am
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
- May 26th, 2026 10:00 am
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
- May 20th, 2026 12:38 pm
PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)
- May 20th, 2026 9:12 am
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
- May 20th, 2026 6:15 am
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
- May 20th, 2026 5:38 am
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
- May 4th, 2026 9:30 am
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
- Apr 13th, 2026 6:00 pm
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
- Apr 7th, 2026 6:00 am
Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream
- Apr 1st, 2026 5:00 am
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
- Mar 31st, 2026 10:00 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
- Mar 13th, 2026 6:35 am
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
- Mar 10th, 2026 8:21 am
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
- Mar 2nd, 2026 6:00 am
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
- Feb 25th, 2026 6:30 am
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
- Feb 23rd, 2026 7:30 am
Jupiter Neurosciences Selected as B2i Digital Featured Company
- Feb 12th, 2026 11:07 am
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
- Jan 28th, 2026 4:00 am
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
- Jan 27th, 2026 8:45 am
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
- Dec 23rd, 2025 6:00 am
Scroll